SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Balderton Capital VI, S.L.P. has updated its ownership disclosure for Sophia Genetics SA, reporting beneficial ownership of 3,301,240 Ordinary Shares of CHF 0.05 per share. These shares are held of record by BCVI, with BCVI Sarl as managing general partner.
The stake represents 4.9% of the outstanding Ordinary Shares, based on 67,579,560 shares outstanding as of June 30, 2025, as reported in a prospectus on Form 424(b)(5). Balderton reports shared voting and dispositive power over all 3,301,240 shares and no sole voting or dispositive power, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.
SOPHiA GENETICS amended its existing credit agreement with Perceptive Credit Holdings to add $25 million of new term loan commitments. This includes a $12.5 million Tranche C that may be drawn subject to customary conditions and a $12.5 million Tranche D that becomes available once trailing twelve‑month revenue exceeds $85 million. Any Tranche C and Tranche D borrowings will mirror existing term loan terms, bear interest at Term SOFR plus 6.25% per year, and mature in 2029.
In connection with the amendment, the company amended and restated a warrant certificate to grant Perceptive rights to purchase up to 275,000 ordinary shares: 75,000 shares exercisable immediately, 100,000 more upon drawing Tranche C, and another 100,000 upon drawing Tranche D. The warrants are exercisable in cash at the holder’s option for up to ten years from each availability date and include customary anti‑dilution adjustments. The company must file resale registration statements for the warrant shares within 30 business days of each availability date and keep them effective until the shares are sold, freely tradable, no longer outstanding, or no longer held by parties with registration rights.
An insider associated with SOPH has filed a notice of proposed sales under Rule 144 for up to 57,001 shares of common stock, with an indicated aggregate market value of 308,945.42. These shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 01/22/2026, and the issuer has 67,847,058 shares outstanding.
The filing shows that 37,001 shares were acquired on 01/22/2026 through an exercise of stock options for cash, and 20,000 founder shares were acquired on 03/18/2021. It also lists a series of prior sales over the past three months under a Rule 10b5-1 trading plan, including individual transactions such as 95,488 shares sold on 01/09/2026 for 491,626.46.
An insider of the issuer of SOPH common stock has filed a Rule 144 notice to sell 7,485 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $40,793.25. The filing states that 67,847,058 shares of common stock were outstanding and lists an approximate sale date of January 20, 2026 on the NASDAQ exchange.
The securities to be sold include 2,999 shares acquired on January 20, 2026 via exercise of stock options for cash, and 4,486 shares acquired on January 18, 2026 as restricted stock units. The notice also details a series of prior Rule 10b5-1 plan sales for Jurgi Camblong over the past three months, with multiple transactions of common stock on various dates from October 2025 through January 2026, each showing the number of shares sold and related gross proceeds.
A shareholder filed a Rule 144 notice to sell 760 shares of common stock with an aggregate market value of $4,142.00 through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares to be sold were acquired as restricted stock units from the issuer on 01/18/2026, with 760 securities recorded as acquired. The filing notes total common shares outstanding of 67,847,058, providing context for the planned sale.
Over the prior three months, 10b5-1 sales for Ross J. Muken included multiple common stock transactions, such as 4,200 shares sold on 01/06/2026 for gross proceeds of $20,013.84, along with several smaller sales in late 2025.
Zhenyu Xu has filed a Form 144 to sell 4,608 shares of SOPH common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange, with an aggregate market value of $25,113.60 and an approximate sale date of 01/20/2026.
The shares to be sold include stock acquired as restricted stock units on 01/18/2026 (608 shares) and founders shares acquired on 06/20/2012 (4,000 shares. In the past three months, Xu has already completed multiple Rule 10b5-1 sales of SOPH common stock, including 4,000 shares on 01/13/2026 for $20,682.40, along with several smaller transactions.
A holder of common stock has filed a Form 144 indicating an intent to sell 5,608 shares through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/20/2026 and an aggregate market value of $30,563.60. These shares were acquired as restricted stock units from the issuer on 04/18/2024.
The notice also lists recent Rule 10b5-1 sales for Philippe Menu, including 5,000–5,006-share transactions on 01/12/2026 and 01/06/2026 and several smaller sales in late 2025, with disclosed gross proceeds for each trade. The filing notes that total common shares outstanding are 67,847,058 at the time of the planned sale.
SOPHiA GENETICS shareholder Daan Guido Maria Van Well has filed a Form 144 notice for a proposed sale of common stock. The filing covers 684 common shares to be sold through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value of $3,727.80 based on the price used in the notice, and notes that 67,847,058 common shares were outstanding.
The 684 shares come from restricted stock units acquired from the issuer on 01/18/2026. The filing also lists recent activity under Rule 10b5-1: sales of 2,056 shares for $9,758.39 on 01/06/2026, 2,051 shares for $9,451.21 on 01/05/2026, 684 shares for $3,168.01 on 12/19/2025, and 685 shares for $2,755.14 on 11/19/2025, all in SOPHiA GENETICS common stock.
An affiliate of SOPH has filed a Rule 144 notice to sell 380 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/20/2026. The filing lists an aggregate market value of $2,071.00 for this planned sale and shows that the shares were acquired as restricted stock units from the issuer on 01/18/2026.
The notice also details prior sales under a Rule 10b5‑1 trading plan for Manuela Valente over the past three months, including 636 shares sold on 01/06/2026 for $3,015.72, 2,085 shares sold on 01/05/2026 for $9,603.93, 381 shares sold on 12/19/2025 for $1,764.45, and 381 shares sold on 11/19/2025 for $1,530.86.
An insider of SOPH filed a notice under Rule 144 to sell 30,959 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $159,748.44. These shares relate to the company’s common stock listed on NASDAQ, with 67,847,058 shares outstanding and an approximate sale date of 01/16/2026.
The securities to be sold include 23,597 shares acquired on 01/16/2026 via a cash exercise of stock options and 7,362 founder shares originally acquired on 03/18/2021. The filing also lists multiple prior Rule 10b5-1 sales over the past three months, including, for example, 95,488 shares of common stock sold on 01/09/2026 for gross proceeds of $491,626.46.